Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 23

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 23
---
 board duties and to otherwise fulfill the responsibilities required of directors. In assessing whether directors and nominees for director have sufficient time and attention to devote to board duties, the nominating and corporate governance committee considers, among other things, whether directors may be “overboarded,” which refers to the situation where a director serves on an excessive number of boards. Our Corporate Governance Guidelines also require that non-employee directors seek approval from the chair of the board of directors or the lead independent director in advance of accepting an invitation to serve on any additional corporate boards or board committee of another company. Members of the board of directors should advise the chair of the board of directors and consult with the chair of the nominating and corporate governance committee in advance of accepting an invitation to serve on the board of another company**

<div align='center'>14</div>

and should only do so to the extent such service would not detract from such director’s ability to fulfill their management functions at Repare. The nominating and corporate governance committee and our board of directors believe that each of our directors has demonstrated the ability to devote sufficient time and attention to board duties and to otherwise fulfill the responsibilities required of directors. Certain proxy advisory firms have adopted overboarding policies, where they will recommend a vote against directors who serve on what the proxy advisory firm believes to be too many boards. Further, certain institutional investors will vote against directors if they believe they are overboarded. These policies are generally intended to address concerns that directors on multiple boards may lack sufficient time to perform their board duties effectively. The nominating and corporate governance committee and the board acknowledge these concerns; however, the nominating and corporate governance committee believes additional factors should be considered in determining whether a director serving on multiple boards should continue to serve on the board. Among other things, the board believes that consideration should be given to the skills and abilities that a director brings to the board, how a director contributes to the diversity and the overall mix of perspectives and backgrounds on the board, and whether the director dedicates the appropriate time, attention and energy to his or her director duties. The board discusses these considerations generally in connection with its evaluation and assessment process and specifically with both current Board members and director candidates who serve on multiple boards of directors. In the case of Dr. Bonita, he has served as a member of our board since September 2019. While he currently serves on four other public company boards of directors in addition to Repare, he is actively engaged in board matters and brings deep strategic knowledge of the healthcare industry to